✦ LIBER ✦

Imatinib Mesylate: : A New Pill for Chronic Myelogenous Leukemia

✍ Scribed by Kavita K. Parmar; Reginald S. King

Book ID: 115305359
Publisher: John Wiley and Sons
Year: 2001
Tongue: English
Weight: 357 KB
Volume: 9
Category: Article
ISSN: 1065-4704
DOI: 10.1111/j.1523-5394.2001.95003.pp.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Imatinib Mesylate in the Treatment of Ch

Imatinib Mesylate in the Treatment of Chronic Myelogenous Leukemia

✍ Gautam Borthakur; Jorge E. Cortes 📂 Article 📅 2004 🏛 Carden Jennings Publishing 🌐 English ⚖ 108 KB

Response of concomitant chronic myelogen

Response of concomitant chronic myelogenous leukemia and chronic lymphocytic leukemia to imatinib mesylate

✍ Ju-Yoon Yoon; Rajat Kumar; Raquel Aloyz; James B. Johnston 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 162 KB

Imatinib Mesylate in Combination with Ot

Imatinib Mesylate in Combination with Other Chemotherapeutic Agents for Chronic Myelogenous Leukemia

✍ Tetsuzo Tauchi; Kazuma Ohyashiki 📂 Article 📅 2004 🏛 Carden Jennings Publishing 🌐 English ⚖ 89 KB

Cardiac tamponade associated with imatin

Cardiac tamponade associated with imatinib mesylate therapy of chronic myelogenous leukemia

✍ James C. Barton; Steven C. Jones; Wade C. Lamberth; Michael T. Reymann; Varian C 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 201 KB 👁 2 views

Resolution of leukemic retinopathy follo

Resolution of leukemic retinopathy following treatment with imatinib mesylate for chronic myelogenous leukemia

✍ John B Christoforidis; Daniel J DeAngelo; Donald J D’Amico 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 100 KB

Persistent neutropenia in chronic myelog

Persistent neutropenia in chronic myelogenous leukemia in chronic phase treated with imatinib mesylate

✍ Yu-Yan Hwang; Eric Tse; Jason C.C. So; Thomas S.K. Wan; Yok-Lam Kwong 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 110 KB 👁 1 views

A physician or a group of physicians considers presentation and evolution of a real clinical case, reacting to clinical information and data (boldface type). This is followed by a discussion/commentary.